Autism spectrum disorder (ASD) is a series of neurodevelopmental disorder with a large genetic component. However, the pathogenic genes and molecular mechanisms of ASD have not been clearly defined. Recent technological advancements, such as next-generation sequencing, have led to the identification of certain loci that is responsible for the pathophysiology of ASD. Three functional pathways, such as chromatin remodeling, Wnt signaling and mitochondrial dysfunction are potentially involved in ASD. In this review, we will focus on recent studies of the involvement of Wnt signaling pathway components in ASD pathophysiology and related drugs used in ASD treatment.
INTRODUCTION
Autism spectrum disorder (ASD) is a phenotypically heterogeneous group of neurodevelopmental syndrome that is characterized by persistent impairment in reciprocal social communication and social interaction, associated with restricted, repetitive behaviors, as well as showing limited interests or activities. 1) ASD is typically apparent during the second year of one's life. In severe cases, deficiencies in developmentally appropriate interest in social interactions may be seen even during the first year of one's life. Verbal and non-verbal problems in social communication have varying manifestations depending on the severity of the disorder as well as several other factors, including appropriate treatment history and environmental support.
Despite the serious characteristics of this disorder, unfortunately, only early detection and special education are considered appropriate treatments until now. Earlier and more appropriate diagnosis and treatment reduce the severity of symptoms and improve adaptability to social life, providing higher quality of life to ASD individuals and their families. Although this earlier diagnosis is critically important due to the severity of this disorder, diagnosis of ASD is not simple and cannot be made by clearcut diagnostic tools. Neuroanatomical changes visualized by magnetic resonance imaging (MRI), computed tomography (CT) and postmortem analysis do not provide clear diagnostic evidence.
2) Genetic heritability estimates for ASD have ranged from 37% to 92% in twin studies. As many as 15% of cases of ASD appear to be associated with a genetic mutation. 1) Some genetic disorders, such as Rett syndrome, fragile X syndrome, and Down syndrome are related to ASD. However, the cause of ASD is often unknown and ASD is considered a heterogeneous disease entity, which has difficulties with early diagnosis. In addition to the trouble of early diagnosis, only two Here, we will focus on recent progress in human genetic studies, since animals' and cellular data were already covered by other reviews. In addition, we will cover potential medications which are related to the Wnt pathway that may ameliorate these defects, thus allowing individuals with ASD to better adapt to our society.
MOLECULAR SIGNATURES OF ASD
As described above, although ASD is a pervasive developmental disorder, the etiology of ASD is poorly understood. Initial population-based studies have failed to identify a single ASD-associated gene and some risk variants, despite the strong heritability of this disease.
Since 2012, number of mutations and gene sets has been identified by multiple approaches, including nextgeneration sequencing, clinically used medications and mouse models. 3, 4) Based on the clinical heterogeneity of ASD as we described above, it is not surprising that multiple genetic mutations exist. Exome sequencing studies have revealed that many single nucleotide polymorphisms (SNPs) presents in ASD individuals and that these genes converge onto the Wnt pathway ( Fig. 1) . Furthermore, mounting evidence indicates that mutations in Wnt pathway-related genes contribute to ASD.
4)
The Canonical Wnt Signaling Pathway in Patients with ASD The Wnt signaling pathway is one of the major mechanisms during embryonic development and tumorigenesis. [5] [6] [7] [8] Wnt proteins are secreted as cysteine-rich glycolipoproteins that act as ligands. Upon stimulation of receptors, such as Frizzled, by Wnt protein association, the Wnt signaling pathway govern multiple processes, including embryonic development and tissue homeostasis. The Wnt signaling pathway is classified into the "canonical" (-catenin-mediated) and "non-canonical" (-catenin-independent) pathways. Recently, genome-wide association studies of the X chromosome have shown that transducin beta-like 1X-linked (TBL1X), a novel component of the Wnt pathway, is related with ASD. 25) Moreover, Chung et al. 25) found intronic SNPs in TBL1X and other studies identified deletions in the Xp22.2 to Xp22.3 region, which includes TBL1X, in autistic girls and women. Because TBL1X interacts with -catenin and binds to the promoter of Wnt target genes, it is plausible that the association between TBL1X and ASD could be mediated by the Wnt pathway.
Consistent with this, certain Wnt target genes have also shown to be associated with ASD. Two intronic SNPs in Engrailed2 were found to be strongly correlated with ASD. 14, 15) p120-catenin Family Members in the Canonical Wnt Pathway p120-catenin, structurally similar to -catenin, is also involved in the canonical Wnt signaling pathway and is modulated by the destruction complex, which includes GSK3, Axin and APC.
26) P120-catenin family members include p120-catenin itself, -catenin, ARVCF (Armadillo repeat protein deleted in velo-cardio-facial syndrome) and p0071. P120-catenin activates Wnt target genes by relieving Kaiso-mediated repression. 27) In addition, activation of Wnt signaling stabilizes p120-catenin in a manner similar to that of -catenin. Intriguingly, Dryk1A has been shown to regulate the stability of p120-catenin and modulates Wnt target genes through the p120-catenin/Kaiso pathway. 28) Dyrk1A has also shown to be associated with ASD from sequencing studies, and mutations in this gene are among the top five ASD-and ID-related genes, 17, 21) suggesting that the Dyrk1A/p120-catenin pathway may be related to ASD. p120-catenin family members are also involved at the point at which Wnt signaling meets small GTPases, such as RhoA and Rac. -catenin, a member of the p120-catenin family, is known to be particularly vulnerable to genetic variations in some human diseases. For example, -catenin harbors significantly more deleterious missense mutations and copy number variations in autistic patients compared to controls. 29, 30) 32) has shown to be a cause of ASD in recent studies of human genetics. 33, 34) However, there is no concrete relationship between the non-canonical Wnt pathway and mental illnesses, including ASD.
Therapeutic Effects of Drugs to Treat ASD May Be Related to Canonical Wnt Signaling
As described above, there are currently no known cures for ASD. There are only two drug, i.e., risperidone and aripiprazole, which have been approved by the US Food and Drug Administration for the treatment of ASD's core symptom. However, both of them are not intended for the complete cure, but only to alleviate symptoms such as irritability in ASD patients. Thus, the development of new therapeutic drugs to treat individuals affected by ASD is urgently required. Some antipsychotics (e.g., risperidone and aripiprazole), mood stabilizers (e.g., lithium) and antidepressants are prescribed to correct the aggressive behaviors associated with ASD. 2) Given the relationship between Wnt signaling and ASD illustrated above, recent studies have evaluated whether medications used to treat autism affect the Wnt signaling pathway. Interestingly, haloperidol and clozapine (an antipsychotic medication), 35, 36) fluoxetine (a selective serotonin reuptake inhibitor) 37, 38) and Ritalin (methyphenidate) 39) have shown to modulate Wnt signaling. Haloperidol is known to transiently increase the phosphorylation of Akt, followed by inhibition of GSK3. 40) Another report also showed that haloperidol promotes the expression of certain Wnt components, such as Wnt-5a, Dishevelled-3 and -catenin. Haloperidol may relay signals through D2 dopamine receptors, which are associated with Dishevelled-3.
41)
Fluoxetine has also been shown to be involved in Wnt signaling, as indicated by mouse studies. Fluoxetine downregulates miR-16, thereby promoting the expression of Wnt2, a brain-derived neurotrophic factor (BDNF). 38) Ritalin is identified to regulate Akt and GSK3, suggesting potential involvement in the Wnt signaling pathway.
39)
Although we must exercise caution when approaching medical treatments related to the Wnt pathway, it is intriguing that some medications used to treat autism directly or indirectly modulate Wnt components, including GSK3. Lithium is also used to alleviate aggression to treat individuals with autism and likely be related to Wnt sig- 
CONCLUSION
Efforts in ASD studies have focused on identifying reliable biomarkers based on multiple approaches, including genetics and neuroimaging. Despite major advancements in studies of neuronal development, there are no specific biomarkers of ASD to support routine clinical use. Neuroimaging studies employing CT and MRI are also controversial. Since early treatment of ASD may increase the efficacy of treatment, finding a reliable biomarker for detecting ASD when illness is not clear yet, could eventually help to apply more accurate and appropriate treatment for patient.
Given that Wnt target genes are thought to be involved in ASD, genetic clusters of Wnt pathway genes could reflect the possibility of ASD and provide an effective approach for categorizing ASD based on their pathophysiology and gene expression criteria. This will contribute to early detection of the ASD phenotype.
Furthermore, we can also search and evaluate certain drugs that are already known to regulate Wnt pathway and assess whether such drugs may be effective for the treatment of ASD based on genetic studies and biomarkers. These studies are expected to reveal important connections between basic neuroscience and clinical studies of mental illness and improve our mental health.
